Lung Cancer

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Merck has withdrawn pembrolizumab from the US market for the treatment of patients with metastatic small cell lung cancer who experienced disease progression on or after platinum-based chemotherapy and at least 1 previous line of treatment.

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).

John V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

The FDA has granted a breakthrough therapy designation to cabozantinib as a potential therapeutic option for patients with differentiated thyroid cancer that has progressed after previous therapy and who are refractory to radioactive iodine.

Margarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.

Bob T. Li, MD, PhD, MPH, discusses the efficacy of sotorasib in patients with KRAS G12C–mutated advanced non-small cell lung cancer, as demonstrated in phase 2 cohort results of the phase 2 CodeBreaK 100 trial.

John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer.

February 23, 2021 - The FDA has approved the PD-L1 IHC 22C3 pharmDx assay, developed by Agilent Technologies Inc, for expanded use in patients with non–small cell lung cancer.

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

February 22, 2021 - The FDA has approved cemiplimab-rwlc monotherapy for use in the frontline treatment of patients with advanced non–small cell lung cancer with a PD-L1 expression level of 50% or higher.

Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical practice.

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for postoperative chemotherapy use and outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Catherine Ann Shu, MD, discusses the mechanism of action of amivantamab in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

February 18, 2021 - Single-agent cemiplimab has been found to result in a significant improvement in overall survival and progression-free survival versus chemotherapy in patients with advanced non–small cell lung cancer who had a PD-L1 expression of at least 50%.

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.